Colorectal Cancer
Conditions
Brief summary
This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer. Data will be collected from patients for approximately 2 years.
Interventions
None listed
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, age \>/=18 years * Proven metastatic colorectal carcinoma * Patients have measurable disease * Patients are eligible to receive first-line Avastin * Patients have signed data release form
Exclusion criteria
* Contra-indication to receive Avastin according to the local labeling * Participation in a clinical study within 30 days prior to enrolment * Patients have any other primary cancer * Concomitant treatment with other biologics * History of other malignant disease in the past 5 years except basal cell carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival in a real life setting assessed by computer tomography | Approximately 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate assessed by computer tomography | Approximately 2 years |
| Response of Avastin according to the sites of metastases assessed by computer tomography | Approximately 2 years |
| Chemotherapy regimens used in combination with Avastin | Approximately 2 years |
| Patient demographics eligible to receive Avastin | Approximately 2 years |
| Safety: incidence of adverse events | Approximately 2 years |
Countries
Lebanon
Outcome results
None listed